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Abstract
Targeting pro-inflammatory events to reduce seizures is gaining momentum. Experimentally, antagonism of inflammatory
processes and of blood-brain barrier (BBB) damage has been demonstrated to be beneficial in reducing status epilepticus
(SE). Clinically, a role of inflammation in the pathophysiology of drug resistant epilepsies is suspected. However, the use
anti-inflammatory drug such as glucocorticosteroids (GCs) is limited to selected pediatric epileptic syndromes and spasms.
Lack of animal data may be one of the reasons for the limited use of GCs in epilepsy. We evaluated the effect of the CG
dexamethasone in reducing the onset and the severity of pilocarpine SE in rats. We assessed BBB integrity by measuring
serum S100b and Evans Blue brain extravasation. Electrophysiological monitoring and hematologic measurements (WBCs
and IL-1b) were performed. We reviewed the effect of add on dexamethasone treatment on a population of pediatric
patients affected by drug resistant epilepsy. We excluded subjects affected by West, Landau-Kleffner or Lennox-Gastaut
syndromes and Rasmussen encephalitis, known to respond to GCs or adrenocorticotropic hormone (ACTH). The effect of
two additional GCs, methylprednisolone and hydrocortisone, was also reviewed in this population. When dexamethasone
treatment preceded exposure to the convulsive agent pilocarpine, the number of rats developing status epilepticus (SE) was
reduced. When SE developed, the time-to-onset was significantly delayed compared to pilocarpine alone and mortality
associated with pilocarpine-SE was abolished. Dexamethasone significantly protected the BBB from damage. The clinical
study included pediatric drug resistant epileptic subjects receiving add on GC treatments. Decreased seizure frequency
($50%) or interruption of status epilepticus was observed in the majority of the subjects, regardless of the underlying
pathology. Our experimental results point to a seizure-reducing effect of dexamethasone. The mechanism encompasses
improvement of BBB integrity. Our results also suggest that add on GCs could be of efficacy in controlling pediatric drug
resistant seizures.
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Introduction
Drug-resistant seizures pose a formidable challenge for drug
development. Recently, the Consensus Proposal by the ad hoc Task
Force of the International League against Epilepsy Commission on
Therapeutic Strategies pointed out that drug resistance is ‘‘a dynamic
process rather than a fixed state’’ and in spite of the available therapeutic
interventions for seizure disorders, the incidence of epilepsies and
mortality associated to status epilepticus remain elevated. More-
over, treatment of childhood epilepsy is of particular interest since it
is widely accepted that ‘‘seizures beget seizures’’; thus, patients who
experience seizures early in life are more likely to develop an
epileptic pathology later in life. In spite of the available therapeutic
interventions for seizure disorders, the incidence of epilepsies and
mortality associated to status epilepticus remain elevated [1].
Clinical [2–4] and translational [4–7] studies have shown that
the gatekeeper at the brain-systemic circulation interface, the
blood-brain barrier (BBB), may be a crucial player in epilepsy [8].
A role of inflammation and BBB dysfunction in the pathophys-
iology of human epilepsies is suspected. Histological studies have
shown BBB dysfunction in human epileptic tissue [9–11]. In
addition, DWI or post-contrast FLAIR MRI changes correspond-
ed to the location of EEG activity in patients with partial status
epilepticus or focal epilepsy [12–18]. Increased CSF albumin, an
index of increased BBB permeability, was also reported at the time
of EEG slow-wave activity [19].
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dysfunction in the pathophysiology of drug resistant epilepsies is
suspected. However, the use of anti-inflammatory molecules such
as glucocorticosteroids (GCs) is for the most part limited to
infantile spasms, Landau-Kleffner or Lennox-Gastaut syndromes
and Rasmussen’s encephalitis. Their efficacy in drug resistant
forms of pediatric epilepsies is still anecdotal [20–22]. A previous
report [23] demonstrated the utility of GCs in other epilepsy
syndromes, but no specific mechanism of action was proposed.
From an experimental standpoint, there is evidence that
inflammation, having significant effects on BBB integrity, affects
normal brain function and contributes to the pathophysiology of
seizures [4,6,11,24,25]. These concepts have been expanded to the
pilocarpine model of seizure [24,26]. Pilocarpine induces acute
peripheral pro-inflammatory changes leading to BBB leakage prior
to SE. These studies also demonstrated that pilocarpine is
relatively impermeant across the BBB and it is therefore unlikely
that this cholinergic drug act directly, or only, on neurons [24,26].
The alternative model based on pilocarpine and lithium given in
combination also encompasses pro-inflammatory events. Of
interest is the fact that the effects of lithium, which has a powerful
immunological action [27], were independent on the schedule of
administration. Lithium potentiated pilocarpine’s action even
when given after pilocarpine, which sheds uncertainty on the
concept of lithium priming the brain cholinergic system. Previous
studies have shown that pharmacological manipulation of
intravascular inflammation and restoration of BBB integrity
reduces seizure onset in the pilocarpine model of TLE [28,29].
These data suggest that the inflammatory process and loss of
BBB integrity may play a pathological role in a broad spectrum of
epilepsies. We further evaluated the effect of anti-inflammatory
agents in experimental seizures, and tested the efficacy of gluco-
corticosteroids. We evaluated the efficacy of anti-inflammatory
treatments in drug resistant pediatric epilepsies, excluding those
conditions already known to benefit from steroidal treatment, i.e.
West, Landau-Kleffner, Lennox-Gastaut syndromes and Rasmus-
sen’s encephalitis [20–22,30]. We analyzed the response to gluco-
corticosteroids, or ACTH, in a pediatric population and analyzed
the results to develop a hypothesis that also takes into account data
obtained from animal experiments where rats were exposed to
convulsive doses of the cholinergic agonist pilocarpine.
The justification for extrapolating data obtained from pilocarpine-
induced SE to drug resistant epilepsy may be considered
inappropriate and one should ideally compare human data to
pilocarpine-treated chronic rats who do not respond to AED. Thus,
two points of asymmetry can be found in the current study, one
related to chronicity of seizures in humans vs. acute nature of BBB
disruption-inducedseizures,aswellastheissueofhumanepilepticvs.
normal brain induced to seize. In fact, to segregate and study drug
resistant rats would constitute the best animal correlate of human
multiple drug resistance to antiepileptic drugs. However, recent
experimental findings suggested that correlates of acute seizures (e.g.,
as triggered by iatrogenic BBB disruption or pilocarpine) are not
dissimilar from chronic seizures. For instance, seizures acutely
induced by intrarterial mannitol have EEG features similar to
pilocarpine seizure and the histological and immunohistochemical
tracts of acute seizures (e.g., cerebrovascular damage) are similar to
the ones observed in the chronic epileptic human brain [31].
Results
Efficacy of dexamethasone: rat study
We first evaluated whether dexamethasone prevents the onset of
pilocarpine-induced seizures in rats. We also quantified seizure-
induced mortality. Experimental details are shown in Figure S1.
These effects are compared to those previously obtained using an
IL-1 receptor antagonist [29].
Figure 1 shows typical EEG traces recorded after injection of
pilocarpine alone (D), after dexamethasone pretreatment (E), or
after blockade of IL-1b receptors (F). The average results are
shown in Figure 1A-C. Note that pilocarpine caused a stereotyped
response consisting of an initial burst of action potentials followed
by a full-blown and persistent SE. When anti-inflammatory
treatment preceded exposure to the convulsive agent (see Figure
S1), the number of rats developing develop seizures was reduced
(Figure 1A). When SE developed, the time of onset was
significantly delayed compared to untreated controls (Figure 3C).
Mortality associated with SE was significantly decreased by
dexamethasone (p=0.02, Fisher test).
Time-joint frequency analysis was performed to examine
changes not immediately apparent by EEG inspections. Note that
the early burst clusters (single asterisks in Figure 2) were reduced in
amplitude and frequency in animals pre-treated with either
dexamethasone or IL1-RA. Severity of SE was also reduced in
treated rats (frequency and amplitude distributions) as shown in
Figure S2.
Evaluation of blood-brain barrier damage
We subsequently compared the integrity of the BBB in animals
treated with pilocarpine and in those pre-treated with dexameth-
asone (Figure 3). We have previously demonstrated that pre-
treatment with IL-RA prevents BBB damage and reduces seizure
occurrence [29]. BBB integrity was evaluated by visualization of
Evans blue extravasation and by measurements of serum levels of
S100b [32]. Note the significant increase of serum S100b levels
and Evan’s Blue signal measured at onset of SE (Figure 3). Both
S100b levels and Evan’s Blue signal were comparable to control
when seizures were prevented or reduced by dexamethasone.
These results are in agreement with animal studies previously
published [5,33]. Remarkably, a decrease in MRI FLAIR
hyperintensity concurrent with seizure reduction was observed in
patients after corticosteroid treatment (see text below and Figure 6).
Serological correlates of dexamethasone efficacy in rats
We analyzed circulating white blood cells (WBCs) to determine
the level of T-lymphocyte activation after pilocarpine or after
dexamethasone followed by pilocarpine. The most important
effect of dexamethasone was a drastic reduction in the number of
circulating T-cells (CD3+, Figure 4A). Among the remaining
CD3+ cells, the relative percentage of CD8+ subpopulation was
significantly affected by dexamethasone (Figure 4C). However, the
latter change may be negligible owing the drastic reduction of total
number of circulating T-cells (Figure 4A). A change in CD4:CD8
ratio consistent with an inflammatory activation was seen after
pilocarpine treatment (Figure 4D, see also [26,34]). Dexametha-
sone significantly reduced the levels of serum IL1-b (Figure 4E).
Efficacy of gluco-corticosteroids or ACTH: human study
We investigated the efficacy of add-on glucocorticosteroids
(GCs) or ACTH treatment in patients affected by drug-resistant
epileptic seizures (see Table S1). Inclusion criteria are described in
the Methods. For the whole study (Figures S3 and S4) we reviewed
data from 43 patients (24 females and 19 males, see Methods) and
a total of 92 GC treatments. The data presented in Figure 5 refer
to 15 patients and 53 treatments with dexamethasone or ACTH.
Mean age at GCs or ACTH treatment was 6.4 6 5.2 years.
Etiology and type of epilepsy are summarized in Table S1. First
seizure occurred between a few days after birth and 13 years of age
Gluco-Corticosteroids and Seizures
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e18200(mean 6 SE: 2 years 6 8 months). Table S1 shows patients’ AED
regimens and, in bold, the AED co-administrated with GCs or
ACTH.
Figure 5A shows the efficacy of dexamethasone or ACTH
treatments. Overall, dexamethasone or ACTH significantly
reduced occurrence of seizures. Overall, the response was variable
ranging from complete reduction of seizures to no benefit from the
treatment. The mosaic plot in Figure 5B shows the distribution of
the overall efficacies (set as $50%) across different etiologies. The
overall results obtained with three different GCs (dexamethasone,
methylprednisolone and hydrocortisone) are shown in Figure S3.
The analysis of efficacy with regard to the type of epileptic
syndrome shows that the best responders were patients with focal
seizures (Figure S3C). There was no correlation between seizure
history (years) and response to treatment (Figure S3D). The latter
result is also shown in the multivariate analysis in Figure S4. We
observed common side effects associated with administration of
GCs (e.g., increased body weight, anxiety and insomnia). Other
side effects were only marginal and did not require cessation of
therapy. Only in few cases (5%) GCs were suspended due to
changes in coagulation, alteration of blood electrolytes or
glycemia.
Discussion
Our results have shown that dexamethasone reduces the
number of rats experiencing status epilepticus (SE) and abolishes
mortality. The mechanism by which dexamethasone lessens
pilocarpine seizure burden encompasses improved BBB function.
This was shown by analysis of dye and marker extravasation in
treated vs. untreated animals. We also studied the efficacy of add-
on gluco-corticosteroids in a population of pediatric drug resistant
patients excluding those syndromes known to be responsive to
GCs and ACTH (L-G, L-K, West or Rasmussen’s). The effect was
beneficial regardless of the pathology and epileptic syndrome. We
have also reported a selected case where a decrease in FLAIR
signal was associated with seizure reduction. Previous studies have
shown that FLAIR hyperintense regions or regions of gadolinium
enhancement correspond to sites of BBB leakage [9,11–14,18,35].
Anti-inflammatory therapy: a human-experimental
parallel
This manuscript presents findings in a format where clinical
data are presented together with animal results. We believe that
this is appropriate because: 1) there is a recognized urgency to
provide rapid therapeutic advancement by comparing clinical and
laboratory results [1,36]; 2) the anecdotal use of corticosteroids in
clinical epilepsy has recently expanded (see below), but its full
potential for widespread use is limited by the lack of scientific
validation of their use. Our study compared the efficacy of
glucocorticosteroids and ATCH: 1) in patients across a wide
spectrum of epileptic etiologies and syndromes, 2) with the
exclusion of those syndromes known to be steroid responsive (i.e.
L-G, L-K, West or Rasmussen’s). We have also compared the
efficacy of steroids in patients with the effects observed in the
Figure 1. Effects of dexamethasone on pilocarpine-induced SE. (A) The number of rats experiencing SE was reduced by anti-inflammatory
treatments. Data are compared to IL-RA treatments [29]. (B) When SE developed, its onset was delayed (control vs. IL1ra p=0.03; control vs. Dexa
p=0.04). (C) Twelve hours mortality associated with pilocarpine seizures was decreased by IL-RA and abolished by dexamethasone (p=0.02). To
attest the efficacy of treatment on survival, seizures were not stopped using barbiturates. (D-E) Examples of EEG recordings show that SE in treated
animals was of lesser intensity compared to pilocarpine alone (see also Figure S2). Data are relative to n=15 rats / group. Asterisks: p,0.05, by paired
t-test and Fisher test.
doi:10.1371/journal.pone.0018200.g001
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direct inhibition of leukocyte-mediated blood-brain barrier
disruption, comparable to the effects of GCs, prevents SE in this
model [28,29].
We are aware that there are significant limitations in our human
study. A major issue is its non-randomized, non-placebo nature. In
addition, there was no standardized dosage or regimen for
corticosteroid treatment. We believe that these are not insur-
mountable limitations for a preliminary, mechanism-related study
because the patients enrolled acted as their own controls. These
patients failed at least three AED medications and were exposed to
all traditional anti-epileptic care that benefits most of their drug-
respondent counterparts. Thus, while use of a placebo arm is
mandatory to evaluate once and for all whether anti-inflammatory
therapy is a valid AED alternative, our studies have shown their
utility at least as an add-on maneuver. The data provided will
hopefully lead to a randomized clinical trial.
Animal data were obtained exclusively from adult rats; this does
not appear to be a crucial limitation since patient age ranged from a
few months to adolescence and no differences in GCs or ACTH
effect were observed with regards to age. Finally, patients received a
combination of GCs and anti-epileptic drugs (Table S1) while
rodents did not.
Non-neuronal mechanisms of epilepsy: role of the blood-
brain barrier
There are several lines of evidence suggesting that the blood-
brain barrier could be a valid adjunctive target for anti-epileptic
drug therapy. Animal studies that have shown that breaching the
BBB is a reliable mean towards decreased seizure threshold [11] or
seizure development [4,6]. More importantly, these animal studies
have been supported by concurrent clinical data showing that
blood-brain barrier disruption (BBBD) causes seizures in human
subjects [4] and that BBBD has a causative link with post-
traumatic epilepsy [3]. We have previously demonstrated that
prevention of BBB failure reduces seizure onset [29]. The data
presented herein further support a pharmacological approach
aimed to prevent BBB failure or restore BBB integrity.
Figure 2. Time-joint frequency analysis of EEG recordings. (A–C) Single asterisk refers to the first seizure episode. The double asterisk shows
the maximal electrographic and behavioral seizures observed under any given condition. The actual EEG recordings are also shown. Time-joint
frequency plots show a reduction of seizure intensity (frequency and amplitude domains, color coded) in treated animals compared to pilocarpine
alone. Data shown refer to 2 hours of EEG recordings. See also Figure S2 for peak area distribution and instantaneous frequency analysis.
doi:10.1371/journal.pone.0018200.g002
Gluco-Corticosteroids and Seizures
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findings. First and foremost is the fact that we have shown that the
efficacy of corticosteroids in pediatric epilepsy is not limited to
epileptic encephalopathies, such as infantile spasms and Rasmussen
encephalitis [25,37,38]. Rather, the effects seemed to be pro-
nounced in focal epilepsy, including those due to focal dysplastic
Figure 3. Dexamethasone reduces BBB damage in pilocarpine-treated rats. BBB integrity was assessed by Evans blue (A) and serum S100b
(B) measurements. Evans blue is an indicator of paracellular leakage while S100b is a surrogate serum marker of the integrity of the cerebrovascular
endothelial interface. Both methods revealed a reduction of pilocarpine-induced BBB damage in dexamethasone-pretreated animals (DEXA-PILO).
Similar efficacy was previously reported for IL1-RA (see [29]). The asterisks refers to p,0.05 by paired t-test, n=5 rats per group.
doi:10.1371/journal.pone.0018200.g003
Figure 4. Hematologic and serologic changes after dexamethasone treatment in rats. (A) Note the drastic decrease of circulating CD3+ T-
lymphocytes after dexamethasone treatment. (B-C) Note the change in the CD4 and CD8 sub-fractions after treatments. Differences were statically
significant for all the pairs but the ones indicated by n.s. (not significant). (D) Correlates of T-lymphocyte decreased activation in dexamethasone
pretreated animals are summarized as CD4:CD8. (E) Serum IL1-b levels were reduced by dexamethasone treatment. The asterisks refers to p,0.05 by
paired t-test, n=5 animals per group.
doi:10.1371/journal.pone.0018200.g004
Gluco-Corticosteroids and Seizures
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recent studies suggesting the efficacy of corticosteroids in focal and
generalized epilepsy [20–22] of different etiologies. The impact of
corticosteroids on seizures during pre-surgical subdural grid EEG
monitoring in drug-resistant children was recently demonstrated. A
reduced seizure frequency was found in dexamethasone-treated
patient compared with untreated [39].
The results of our experimental study support the hypothesis
that inflammatory mechanisms and BBB damage could contribute
to seizure generation and severity [40,41]. We confirmed the
pattern of WBC activation in the experimental model used [29].
Interestingly, in rats pre-treated with dexamethasone, we observed
a decrease in SE severity (Figures 1 and 2) at time of decreased
number of circulating T-cells (Figure 4) and reduction of BBB
damage (Figure 3).
The efficacy of corticosteroids observed in patients supports the
hypothesis that seizures of different etiologies (including those due
to congenital malformations or acquired brain damage) may be
aggravated by inflammatory mechanisms and BBB disruption.
The hypothesis linking BBB damage to seizures is in agreement
with histological studies that have shown BBB dysfunction in
human epileptic tissue and with MRI studies showing changes
corresponding to the location of EEG activity in patients with
partial status or focal epilepsy [11,12,14–18,25]. Our clinical study
design did not include the systematic evaluation of MRI before
and after treatments, nevertheless the decrease in FLAIR
hyperintensity concurrent with seizure reduction after steroid
treatment (Figure 6) suggests the hypothesis that restoring BBB
integrity may be one of the mechanisms involved in the
antiepileptic action of corticosteroids. A prospective ad hoc MR
study is mandatory to confirm or disprove this notion.
Experimental approximation of clinical epilepsy
One obvious issue is that we used only pilocarpine as a model of
seizures. This is not, in our opinion, a crucial limiting factor
inasmuch that this model has been historically used to model
human disease and also because several features of this model have
common traits with human epilepsy [42,43]. For example, it was
shown that pilocarpine seizures cause cerebrovascular changes
which are consistent with those seen on MRI of patients [43].
These consist of homeostatic failure leading, in patients, to MRI
hyperintensity and in animals to increased extravasation of
intravascular (Evans blue) or cerebral-to-serum (S100b) indicators
(Figure 3). In addition, pilocarpine induces seizures by an
unexpected immunologic activation mediated by specific receptors
and adhesion molecules [28,29]. These same molecules are the
target of corticosteroids, and depletion of these adhesion molecules
appears to protect against pilocarpine or clinical seizures. While
the link between steroidal efficacy and BBB needs to be fully
demonstrated in patients, we believe that the results we present
herein are adequate to warrant an in-depth investigation of the
BBB-corticosteroid-epilepsy relationship.
If BBB leakage is the main initiator of seizures, and if BBB
repair is protective against neurological disease, which are the
mechanisms involved? The experimental evidence provided
herein, together with previous findings [25,26,28], point to an
inflammatory-induced damage of the BBB. Corticosteroids have a
profound effect on human and rodent BBB permeability
[25,33,44–47]. Moreover, corticosteroids have an impact on the
number of circulating T-cells. Downstream signaling by IL1-b
appears to be a common thread in pilocarpine-induced seizures
(this paper and [25,29,48]). It therefore seems reasonable to
assume that the immune system acts in concert to produce BBB
leakage and seizures, while the counteraction of corticosteroids has
the opposite effect [48]. These results further suggest that seizures
and inflammation belong to the same chapter of neuro-
immunology, as also shown recently [49].
An important correlate of our findings is the fact that animal
data strongly suggest that anti-inflammatory treatments have a
pronounced effect on survival, which in the pilocarpine model is
usually achieved only by stopping SE with diazepam or
Figure 5. Efficacy of dexamethasone and ACTH in drug resistant pediatric epilepsy. Data relative to the efficacy of methyl-prednisolone
and hydrocortisone are presented in Figure S3. (A) A total of 53 treatments were evaluated. Treatments were administered as described in the
Methods and Table S1. Seizures were assessed by behavioral and EEG observations. The values reported refer to decrease in seizure burden
compared to baseline EEG seizure quantification. T-test was used to assess significance. (B) Mosaic plot showing the correlation between etiology of
epilepsy and likelihood of a response $50%. Note that etiology did not always predict response. Noteworthy, dysplasia and other non-
encephalopathic diseases responded to the treatments. Cryptogenic seizures were least affected. Bar width is proportional to the number of
observations. Colors refer to the response as indicated in the inset.
doi:10.1371/journal.pone.0018200.g005
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treatment of catastrophic epilepsies in pediatric or adult settings.
It is important to note that a non-inflammatory mechanism for
steroidal action exists, namely the modulation of GABA receptors
[51]. We are aware of this possible interpretation of results which
seems however unlikely given that a number of corticosteroids,
ACTH, or IL1-RA exerted the same effects. While our results
cannot fully confirm or rule out a specific neuronal action of
steroids the fact that the response spanned across a wide range of
anti-inflammatory molecules makes this unlikely.
Finally, while steroidal treatment showed promise in our study,
the fact remains that the use of potent and potentially harmful
anti-inflammatory drugs is not a viable long-term option. The
treatment, when successful, had to be repeated once the efficacy
waned. This is likely due to traditional, concurrent etiologic
mechanisms including cortical dysplasia, other brain lesions, etc.
The proposed scenario thus implies that: 1) reduced BBB function
on an abnormal cortical/hippocampal background facilitates
seizures; 2) The lesional tissue itself promotes BBB dysfunction,
cooperating towards a further decrease of the threshold for
seizures; 3) Steroids ‘‘repair’’ the BBB while having no impact on
circuital and structural abnormalities. This reduces seizure
probability; 4) The anti-inflammatory efficacy decreases over
time. This vicious cycle, to be interrupted requires simultaneous
targeting of neurons and endothelial cells. In multiple drug
resistant patients, AEDs are obviously not sufficient to reduce
hypersynchronous firing: a new therapy combing anti-inflamma-
tory potency with neuronal targeting may be the necessary and
winning combination.
Conclusions
Our results suggest the potential application of GCs in treating
drug resistant seizures and support further studies assessing the
effect of GCs in experimental chronic seizures. A prospective
randomized trial is needed to elucidate the potential benefit of
add-on GCs therapy in drug resistant epilepsy.
Methods
Rodents
Rats were housed in a controlled environment (2161uC;
humidity 60%; lights on 08:00 AM - 8:00 PM; food and water
available ad libitum). Procedures involving animals and their care
were conducted in conformity with the institutional guidelines that
are in compliance with international laws and policies (EEC
Council Directive 86/609, OJ L 358, 1, Dec.12, 1987; Guide for
the Care and Use of Laboratory Animals, U.S. National Research
Council, 1996). Cleveland Clinic IACUC approved the protocol
number 08491 for the performance of the presented experiments.
Induction of seizures and drug treatments
Rats (male Sprague-Dawley 225–250g) were injected with
methylscopolamine (0.5 mg/kg, i.p., Sigma-Aldrich) and 30
minutes after with pilocarpine (340 mg/Kg, Sigma-Aldrich). We
have analyzed data obtained from a total of 45 rats (see also Figure
S1B). Development of seizure and status epilepticus was evaluated
by behavioral (Racine’s scale) and EEG assessment. Dexameth-
asone sodium phosphate (APP Pharmaceutical, IL, USA) was
administered 2 mg/kg, i.p. twice a day for 2 days prior
Figure 6. Radiologic indices of successful treatment with dexamethasone. The seizure reducing effect of dexamethasone (B) was paralleled
by a decrease in FLAIR hyperintensity.
doi:10.1371/journal.pone.0018200.g006
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was also used but did not exert any discernable effects (data not
shown). IL-RA data included here are relative to [29]. IL-RA was
administrated in the tail vein (30 mg/kg) 2 hours before scopol-
amine/pilocarpine treatment.
Schedule of treatment-sampling and sacrifice
The number of rats used, timing of drug treatments, blood
drawings-analysis and animal sacrifice are indicated in Figure S1.
Note that, blood samples were taken at baseline, after each
treatment and immediately before (or at onset) of status epilepticus
(SE), as evaluated by EEG and behavioral (Racine’s Scale)
assessments. This methodology has been used in the past by us
and other to evaluate the presence of BBB damage and
inflammatory process preceding seizure onset [24,26]. Rats that
developed SE despite of dexamethasone pre-treatment were either
sacrificed at SE onset to determine BBB damage and serological
correlates or followed by EEG/behavioral analysis up to 12 hours
(seizures were not stopped with barbiturate) to analyze seizures
severity and mortality rate (see Figure S1A).
Rodent EEG recording and video monitoring
Stereotactic electrode implantation was performed in rats under
isofluorane anaesthesia, using the Kopf stereotactic frame.
Approximately, half of the rats used were implanted. Four stainless
steel screws (MX-0090-2, Small Parts Inc., Miami, Florida) were
placed bilaterally on the dura mater of the fronto-parietal cortex.
A prefabricated Pinnacle pre-amplifier was connected to the
screws. The system has three bio-potential channels - 2 EEG and 1
EMG. Prefabricated head implants (Pinnacle Inc., USA) ensured
accurate electrode positioning and reliable, robust contacts. Cable
artifacts are eliminated by pre-amplification of the EEG and EMG
waveforms at the animal’s head. EEG data were sampled a rate of
200 Hz. All data are transferred via a USB connection to a PC.
Rats were left unrestrained for 2 weeks to recovery from surgery
before EEG recordings were performed. Each rat was kept in a
separate cage under 12-hours dark-light cycles with free access to
food and water. Origin Microcal 7.0 and Diadem (National
Instruments) was used in conjunction to the acquisition system for
data analysis (e.g., time-joint frequency analysis).
FACS and IL-1b ELISA
The schedule of blood sampling is illustrated in Figure S1A.
Blood was collected from the tail vein using a fixed catheter
(Venisystem, Abbocath, 22G, 300–500 ml/sample). For FACS
analysis, 150 mL of whole blood were incubated with a
combination of specific antibodies recognizing T-cell subpopula-
tion (CD3+). In particular mouse anti-rat CD8a-FITC, CD3-R-
PE and CD4-PE-Cy5 (BD-Pharmingen) were added (2 mL, 5 mL
and 5 mL respectively) to blood samples. Blood samples were
analyzed by the FACS-Core facility at the Cleveland Clinic. IL-1b
ELISA–tests was purchased from Pierce Biotechnology Inc. and
performed as described by the vendor.
Blood-brain barrier integrity assessment
BBB status was assessed using two independent modalities:
serum S100b and brain Evan’s Blue extravasation [29,32]. Blood
samples were obtained from the tail vein and brains were collected
after sacrifice (control, dexamethasone-treated or at onset of SE,
n=5 rats/group). S100b: blood samples were collected at the
times indicated in Figure S1. Blood samples were centrifuged at
1,2006g for 10 min, and the supernatant serum stored at 280uC.
The S100b concentration was measured using the Sangtec 100
ELISA method (Diasorin, Stillwater, MN, U.S.A.). Evan’s Blue:w e
evaluated the pattern of BBB leakage measuring fluorescent signal
present in the brain. The fluorescent solution was prepared
reconstituting 2 g of Evans Blue in 100 ml of phosphate buffered
saline (0.1 M PBS). The solution was stirred at room temperature
in the dark. The solution was infused in the left heart ventricle
(2 ml/rat at rate of 1 ml/min). Presence of gross leakage in treated
and control animals was evaluated by fluorescent in vivo imaging
signaling (IVIS). Brains were placed in the IVIS chamber and
background fluorescence was set as zero. Digitalized signals were
created following a blue-to-red scale based on the regional
distribution of fluorescent signal.
Human subjects
The study was conducted according to the Declaration of
Helsinki Criteria and to the procedures for compassionate drug
administration approved by the Ethic Committees of Carlo Besta
Institute (Milan, Italy). Oral informed consent from was obtained
from parents by specialized neurologists also author of this
manuscript. Administration of GCs was considered compassion
care since all patients had intractable life threatening seizures. We
reviewed the clinical data of 43 patients (Table S1) of the Carlo
Besta Neurological Institute (Milan, Italy). All the patients had a
known history of intractable seizures and antiepileptic treatment
with conventional AEDs was administered (Table S1). We
excluded patients with a history of epileptic syndromes known to
respond to steroids (i.e., West, Lennox-Gastaut, Landau-Kleffner
and Rasmussen encephalitis) as well as patients affected by
documented inflammatory brain disease. All the subjects received
steroid treatment on an in-patient basis.
Different treatments were employed in different patients:
ACTH, dexamethasone, methylprednisolone, and hydrocortisone.
Details on glucocorticoids (GCs) or ATCH dosage are summa-
rized in Table S1. Patients received GCs or ACTH therapy
because of one of the following: 1) .50% increase in seizure
frequency; 2) development of non-convulsive status epilepticus;3 )
presence of epilepsia partialis continua (EPC). Before GCs or ATCH
treatment, patients were evaluated by a team of neurologists,
physiologists, and underwent EEG and routine laboratory
examinations. Antiepileptic treatments were maintained during
the steroid course (Table S1).
Steroidal treatment was, when successful, repeated in case of
seizure recurrence. For this reason, the number of treatments
reported is greater than the number of patients (treatments=92,
see Table S1). GCs or ATCH therapy was considered successful
when: 1) seizure frequency decreased by 50%; 2) status epilepticus
was stopped; 3) or when epilepsia partialis continua (EPC) was
stopped/reduced enough to allow voluntary movement in the
affected body district. Duration of treatment was limited to acute
dosing, which was repeated when the initial response was
beneficial. The effects of length of treatments and efficacy/toxicity
of chronic use are not presented herein, since this study design
only addressed a proof of principle use of steroids in pediatric
epilepsy.
Statistical analysis
Spike detection, spike area and instantaneous frequency
calculation were performed using pClamp 9.2. Statistics were
performed with aid of Origin 7.0 (Microcal) and Jump 7.0; data
were considered to be significantly different when p,0.05 (by
ANOVA or paired t-test for multiple comparisons). Normal
distribution of data was evaluated with Wilk–Shapiro routine.
Mosaic plots were graphed with Jump 7.0 and transferred to
CorelDraw as metafiles. The Diadem (National Instruments)
Gluco-Corticosteroids and Seizures
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test was used (Jump 7.0) to evaluate the significance of probability
of SE and incidence of mortality between groups of animals.
Supporting Information
Figure S1 Experimental procedures. (A) After drug treat-
ment, rats were sacrificed either at SE onset (e.g., to evaluate BBB
integrity and FACS -IL-1b analysis) or after 12 hours (e.g., to
evaluate EEG changes and mortality). (B) The total number of rats
used and the detailed treatment schedule is provided. IL-RA data
are relative to [29]. See also Methods Section.
(TIF)
Figure S2 Number of events, peak area and instanta-
neous frequency distribution. EEG traces from pilocarpine
alone, dexamethasone, or IL-RA pretreated were analyzed using
the event detection routine in ClampFit 9.2. Event threshold was
set as 2X baseline across all traces. Analysis of typical traces is
provided. Different treatments are indicated by different colors.
Pilocarpine SE was characterized by the highest frequencies of
events. Spike area (time x amplitude) was also greater compared to
dexamethasone (red). (B) IL-RA pre-treatment lead to qualitatively
and quantitatively similar results.
(TIF)
Figure S3 Summary of the efficacy of glucocorticoster-
oids (dexamethasone, methylprednisolone and hydro-
cortisone) and ACTH in drug resistant pediatric epilep-
sy. (A) A total of 92 treatments were evaluated. Treatments were
administered as described in the Methods and Table S1. Seizures
were assessed by behavioral and EEG observations. The values
reported refer to decrease in seizure burden compared to baseline.
(B) Mosaic plot showing the correlation between etiology of
epilepsy and likelihood of a response $50%. C) Although GCs
and ACTH were effective across all epileptic syndromes, seizure
reduction was more prominent in focal epilepsy patients. D)
Therapeutic response (set as $50%) did not correlate with seizure
history.
(TIF)
Figure S4 Summary of a multivariate analysis of
patients’ data, serological measurements and drug
efficacy. Significant p value (,0.05) is indicated by a red square.
Among the variables analyzed the following are here described: 1)
age was not a factor influencing GCs or ACTH efficacy; 2) a trend
toward significance was observed for the following pairs: efficacy
and number of neutrophils, efficacy and number of WBC. A larger
population study is required to assess full significance of leukocytes
variation in relation to seizure burden and reduction.
(TIF)
Table S1 Summary of Patients’ data.
(DOC)
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